Tesaro, Inc. is an American pharmaceutical company that focuses on drug development for cancer treatments.

According to the Complaint, this action stems from a proposed transaction announced on December 3, 2018 (the “Proposed Transaction”), pursuant to which TESARO, Inc. (“TESARO” or the “Company”) will be acquired by GlaxoSmithKline plc.

On December 14, 2018, Defendants filed a Solicitation/Recommendation Statement (the “Solicitation Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed
Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on March 5, 2019.